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Case Report
Introduction
Drug-induced neurotoxicity is a rare adverse reaction associ-
ated with carbapenem antibiotics.1-3 The data demonstrating a 
neurotoxic association for carbapenems stems from animal 
models, observational analyses, randomized controlled trials, 
meta-analysis, and case reports.1-3,7-14 Imipenem is considered 
to have the highest incidence of neurotoxicity among carbapen-
ems, although there are published literature that refute this con-
sensus.3,7,15-19 Encephalopathy is a type of neurotoxicity that is 
defined as a diffuse disease of the brain that alters brain func-
tion or structure. Encephalopathy is characterized by an altered 
mental state with additional symptoms including progressive 
loss of memory and cognitive ability, personality changes, 
myoclonus, nystagmus, tremor, and seizures. Carbapenem neu-
rotoxicity is often evaluated and reported in terms of seizures, 
and data on encephalopathy are limited. There are case reports 
of ertapenem neurotoxic effects consisting of encephalopathy 
in patients with end-stage renal disease or mild renal dysfunc-
tion. We report a patient with normal renal function who devel-
oped ertapenem-induced encephalopathy manifesting as 
altered mental status, hallucinations, and dystonic symptoms.
Case Description
A 67-year-old male with a history of normal cognitive func-
tion was admitted with complaints of hallucinating for 
approximately 1 week. Past medical history was significant 
for chronic lumbar spine methicillin-sensitive Staphylococcus 
aureus osteomyelitis maintained on life-long cephalexin 
suppression (discontinued 2 weeks before presentation), 
non-Hodgkin’s lymphoma in remission for 20 years, hyper-
tension, atrial fibrillation, type 2 diabetes for 13 years (cur-
rent HgA1C 8.2), ankylosing spondylitis, and esophagitis. 
Table 1 lists the medication history at hospital admission. 
The patient’s chronic lumbar spine osteomyelitis led to 
numerous surgical manipulations of the spinal region, the 
last of which was in 2012. The spine site became reinfected 
in 2015 requiring hardware removal and multiple surgical 
debridements. The spinal abscess wound cultures were posi-
tive for Enterobacter sp, Lactobacillus sp, and Candida gla-
brata. Treatment was initiated with oral fluconazole 600 mg 
daily, piperacillin/tazobactam 4.5 g every 6 hours (changed 
to ertapenem 1 g daily), and a wound vacuum-assisted clo-
sure dressing placed over the surgical site. Encephalopathic 
symptoms including hallucinations began 5 days after 
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Drug-induced neurotoxicity is a rare adverse reaction associated with ertapenem. Encephalopathy is a type of neurotoxicity 
that is defined as a diffuse disease of the brain that alters brain function or structure. We report a patient with normal renal 
function who developed ertapenem-induced encephalopathy manifesting as altered mental status, hallucinations, and dystonic 
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utilized the Naranjo Scale to estimate the probability of an adverse drug reaction to ertapenem. Our patient received a 
Naranjo Scale score of 7, suggesting a probable adverse drug reaction, with a reasonable temporal sequence to support our 
conclusion.
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ertapenem was started. Clinical examination at the bedside 
revealed the patient to be responsive and alert but clearly 
lethargic with clouded sensorium, lip smacking, mild 
asterixis and tremor, and incoherent speech. Through the 
entire hospitalization the patient remained afebrile with nor-
mal vital signs. Leukocyte count remained normal at an aver-
age of 5.5 × 109/L (6 readings). His renal function remained 
stable and electrolytes were normal, as were random glucose 
checks, thyroid function test, and ammonia level (Table 2). 
Calculated creatinine clearance by the Cockcroft-Gault 
equation was 66 mL/min on admission (Table 2). Urine and 
repeated blood culture sets were negative. Urinalysis was 
unremarkable. Arterial blood gas was noncontributory. Chest 
radiograph revealed a left upper lobe pulmonary nodule but 
subsequent thoracic computed tomography scan with con-
trast showed no contributing pathology and was stable. 
Computed tomography of the head revealed no acute intra-
cranial pathology. Electroencephalogram was also normal. 
An extensive literature review of ertapenem, neurotoxicity, 
and encephalopathy yielded case reports of ertapenem-
induced central nervous system (CNS) events. Ertapenem 
was stopped and ceftazidime 2 g every 8 hours was started. 
His hallucinations and related neurological symptoms began 
to improve and the patient recovered to his baseline mental 
status within 2 days.
Discussion
Our report demonstrates a case of ertapenem-induced 
encephalopathy manifesting as hallucinations and altered 
mental status. The patient’s symptoms improved dramati-
cally following ertapenem discontinuation, consistent with 
case reports describing ertapenem neurotoxicity in renal 
dysfunction. No other medication regimen changes were 
done during the hospitalization, and no medical history was 
identified as a cause of the encephalopathy. Since clinical 
evidence strongly suggested ertapenem causality, we uti-
lized the Naranjo Scale to estimate the probability of an 
adverse drug reaction to ertapenem.20 Our patient received a 
Naranjo Scale score of 7, suggesting a probable adverse 
drug reaction, with a reasonable temporal sequence to sup-
port our conclusion (Table 3).
Imipenem has demonstrated the highest neurotoxic 
adverse reaction rates among the carbapenems, while drug-
induced encephalopathy is rare with ertapenem and other 
carbapenems. Imipenem neurotoxicity rates in adults range 
from 0.4% to 10%, compared to less than 1% for merope-
nem, doripenem, and ertapenem.3 Specifically for ertape-
nem, postmarketing literature documenting ertapenem 
neurotoxicity is scarce and limited to case reports with 
patient-related factors (eg, renal dysfunction, history of cen-
tral nervous system disorders).10,11,21-25 Published case reports 
include the following:
•• Duquaine et al reported 2 patients who developed 
unusual mental status changes while receiving ertape-
nem 1 g daily.21 One patient had acute renal dysfunc-
tion prior to starting therapy. Symptoms resolved on 
drug discontinuation for both patients.
•• Wen et al reported 2 patients with advanced renal fail-
ure who received ertapenem at 500 mg daily and sub-
sequently developed acute prolonged neurotoxicity.22 
Baseline mental function returned 2 weeks after dis-
continuation of therapy for both patients.
•• Lee et al reported 4 patients on hemodialysis that devel-
oped unexplained central nervous system toxicity and 
Table 1. Medication History at Time of Admission.
Atorvastatin 80 mg daily
Cephalexin 500 mg every 12 hoursa
Diltiazem 120 mg daily
Ertapenem 1 g dailyb
Fluconazole 600 mg daily
Gabapentin 300 mg 3 times per day as needed
Glipizide 10 mg twice daily
Metformin 500 mg twice daily
Metoprolol tartrate 25 mg twice daily
Rivaroxaban 20 mg daily
aCephalexin was discontinued 2 weeks priors to presentation for altered 
mental status.
bErtapenem was administered intravenously; all other medications were 
orally administered.
Table 2. Summary of the Blood Test Results of Our Patient on 
Admission.
Parameters Readings Normal Ranges
White cell count 6.8 3.6-11.1 K/mm3
Hemoglobin 10.5 12.9-16.1 g/dL
Platelet 476 165-353 K/mm3
Sodium 136 135-145 mmol/L
Potassium 4.3 3.5-5.1 mmol/L
Blood urea nitrogen 16 7-26 mg/dL
Creatinine 1.2a 0.5-1.3 mg/dL
Calcium 9 8.4-10.2 mg/dL
Albumin 2.2 3.5-5.0 g/dL
Total bilirubin 0.3 0.2-1.2 mg/dL
Alkaline phosphatase 107 40-150 U/L
Alanine aminotransferase 102 0-55 U/L
Aspartate aminotransferase 76 5-34 U/L
Ammonia 29 18-72 Umol/L
Thyroid-stimulating hormone 5.93 0.35-4.94 µIU/mL
Free T4 0.95 0.70-1.48 ng/dL
aThe serum creatinine ranged from 1.1 to 1.2 mg/dL over 2 years prior 
to admission. The creatinine clearance calculation by the Cockcroft-Gault 
method was 66 mL/min using adjusted body weight (actual body weight 
92 kg; adjusted body weight 78 kg; ideal body weight 68 kg). Regardless 
of the weight utilized (ideal, actual, or adjusted), the patients ertapenem 
dose of 1 g daily is correct based off creatinine clearance dosing recom-
mendations.19
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hallucinations after receiving 500 mg.23 Discontinuing 
the drug led to symptom resolution in all 4 patients.
•• Shea et al reported a patient with moderate renal 
impairment who developed encephalopathy with 
delayed recovery of 2 weeks. The patient exhibited a 
full recovery after cessation of ertapenem.24
•• Oo et al reported 2 cases of ertapenem neurotoxicity, 
including psychosis and encephalopathy.10 Symptoms 
resolved within 3 and 10 days of discontinuing 
ertapenem.
•• Kong et al reported a case of ertapenem-induced 
visual hallucinations.11 Subsequent re-introduction of 
ertapenem resulted in almost identical symptoms. 
Complete resolution of symptoms occurred after dis-
continuation of ertapenem, as observed in our case 
study.
Risk factors for carbapenem neurotoxic adverse reactions 
include the following: (1) basicity strength of the C-2 amino 
group for carbapenems; (2) accumulation in the CNS, spe-
cifically in cases of excessive dosage or impaired renal clear-
ance; (3) patients with CNS disorders (eg, past medical 
history of seizure disorder).5,25-27 Among these risk factors, 
molecular structure is the most important compound-related 
factor and renal insufficiency is the most important patient-
related factor predisposing to carbapenem neurotoxicity. 
Pharmacokinetic-related factors may also influence the neu-
rotoxic reactions related to ertapenem. Neurotoxicity risk 
factors include the following:
•• Compound related: Carbapenems have discordant 
rates of neurotoxic adverse reactions potentially 
because of structural differences within side 
chains.1-3,6-9 Available data demonstrate the probable 
neurotoxic mechanism is via interactions with the 
γ-amino butyric acid receptor A (GABA
A
).8,9 This 
interaction is through the side chain on the second 
carbon atom (C-2) in the carbapenem nucleus. A car-
bapenem with a basic C-2 side chain increases the 
binding to GABA
A
 resulting in higher neurotoxic 
activity in animal models. Because of a basic C-2 
side chain, imipenem has a higher tendency to pro-
duce neurotoxic adverse reactions compared to 
meropenem because of the less basic side C-2 side 
chain of meropenem.1-3,6-9 Conversely, ertapenem 
has an acidic carboxyl group at the C-2 position, is 
expected to have the lowest binding to GABA
A
, and 
subsequently is thought to have the lowest potential 
for neurotoxic activity.
•• Patient related: Patient-related risk factors for car-
bapenem neurotoxicity include advanced age, history 
of CNS disease, renal insufficiency, low body weight, 
and concurrent use of drugs that are nephrotoxic or 
that may lower the seizure threshold.4,5 Published lit-
erature demonstrates that renal dysfunction (end-stage 
renal disease or mild renal dysfunction) is the primary 
patient-related factor.
•• Pharmacokinetic related: There are pharmacokinetic 
parameters of ertapenem that also could contribute to 
the drug’s ability to affect the CNS. These factors 
include a high volume of distribution, high lipophilic-
ity, high protein binding, strong CNS penetration, and 
metabolites that can also inhibit GABA receptors.8,9
Our patient is unique because he had no baseline cerebro-
vascular disease or history of renal dysfunction. Characteristics 
of our patient that may have contributed include his age (67), 
low albumin levels, potential overestimation of his renal 
Table 3. Naranjo Adverse Reaction Probability Scale.
Question Yes No Do Not Know Case Report Score
Are there previous conclusive reports about the reaction +1 0 0 +1
Did the adverse event appear after the suspected drug was administered? +2 −1 0 +2
Did the adverse reaction improve when the drug was discontinued or a 
specific antagonist was administered?
+1 0 0 +1
Did the adverse event reappear when the drug was re-administered? +2 −1 0 0
Are there alternative causes (other than the drug) that could on their own 
have caused the reaction?
−1 +2 0 +2
Did the reaction reappear when a placebo was given? −1 +1 0 0
Was the drug detected in blood (or other fluids) in concentrations known to 
be toxic?
+1 0 0 0
Was the reaction more severe when the dose was increased or less severe 
when the dose was decreased?
+1 0 0 0
Did the patient have a similar reaction to the same or similar drugs in any 
previous exposure?
+1 0 0 0
Was the adverse event confirmed by any objective evidence? +1 0 0 +1
Total score = 7a
aTotal score 5 to 8 = probable adverse drug reaction, with a reasonable temporal sequence to support the reaction.
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function, and prior cephalexin suppression. Ertapenem is 
highly protein bound—up to 95% bound to albumin; thus, our 
patient may have been exposed to excessive free drug as his 
albumin was low. In addition, ertapenem is renally excreted, 
up to 80%, requiring dosage adjustments for creatinine clear-
ance of less than 30 mL/min. Our patient’s creatinine clear-
ance could have been overestimated as serum creatinine 
measurements are not as accurate in the elderly.28 The creati-
nine clearance calculation of 66 mL/min utilized the adjusted 
body weight of the patient. Regardless of the weight utilized 
(ideal, actual, or adjusted), the patients ertapenem dose of 1 g 
daily is correct based off creatinine clearance dosing recom-
mendations (Table 2). Furthermore, while there is no known 
interaction between cephalexin and ertapenem, it is possible 
that cephalexin suppression could have had an impact on this 
case. However, the patient tolerated the cephalexin while 
receiving and tolerated ceftazidime after developing the CNS 
symptoms. Furthermore, cephalexin was discontinued 2 
weeks prior to presentation; therefore, it is unlikely that cepha-
lexin has a role in the symptoms.
Previous studies and reviews on carbapenem antibiotics 
indicated that the high degree of neurotoxicity is not a class 
phenomenon for carbapenems, and that there are carbapen-
ems that have a lower degree of neurotoxicity. Therefore, 
non-imipenem carbapenems are thought to be safely admin-
istered at high doses and are useful in the treatment of CNS 
infections. While this may be true, non-imipenem carbapen-
ems have demonstrated a neurotoxic potential, and our case 
report demonstrates a carbapenem with an acidic carboxyl 
group administered to a patient with no neurotoxic risk fac-
tors can still develop encephalopathy. Our case report aims to 
add to the growing body of literature of ertapenem-induced 
neurotoxicity with the goal of increasing education regarding 
the potential for these neurotoxic effects.
Conclusion
We are sharing our experience of a patient with normal renal 
function who developed neurotoxicity following standard dos-
ing of ertapenem. The goal of this case report is to draw atten-
tion to the neurologic and encephalopathic potential of 
ertapenem. Identifying ertapenem as a potential causative 
agent of these conditions can spare unnecessary investigations 
and health care expenditures. In our patient, supportive care 
following discontinuation of ertapenem resulted in complete 
resolution of his hallucinations and altered mental status.
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